 And that means interacting because often this is uncertainty. We're talking in a lot of cases, the best cases, right? We're talking about drugs that are treating conditions that don't have treatments now. And so nobody really knows how to evaluate them. And so there has to be that collaboration, but that doesn't mean what they call regulatory capture. That simply means a high-level professionalism.